Business
Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application
Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application.
About this update from Enzolytics Inc.
[{"type":"text","content":"Third Tranche of $1.2 Million Financing CompletedCOLLEGE STATION, TX / ACCESSWIRE / January 19, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for "Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment" and has received the third tranche of the $1.2 million dollar financing.The Company expects to file the disclosure section of the Annual Report pursuant to the Pink Basic Disclosure Guidelines by Tuesday afternoon. To maintain a current status with OTC Markets, the Company plans on filing the Financial Statements section of the Annual Report as well under the Pink Guidelines while the Audits for the December 31, 2020 and 2019 calendar year ends are completed.CEO Charles Cotropia stated, "We continue to make progress on the various areas of focus of ENZC's management team. We are taking the approach on the Annual report filings to ensure that we maintain the current status but are putting our effort into finalizing the audited statements as quickly as possible. The updates on the validation batch of ITV-1, grants, Web Page and potential collaborations will be forthcoming."About Enzolytics, Inc.:Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.About BioClonetics Immunotherapeutics, Inc. BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the ...